Biocept Net Income From Continuing Ops from 2010 to 2026
| BIOCQ Stock | 0.0001 0.00 0.00% |
Net Loss | First Reported 2010-12-31 | Previous Quarter -28.9 M | Current Value -30.3 M | Quarterly Volatility 6.8 M |
Check Biocept financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biocept's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.4 M, Interest Expense of 300.3 K or Selling General Administrative of 12.6 M, as well as many indicators such as Price To Sales Ratio of 0.13, Dividend Yield of 0.0 or PTB Ratio of 0.32. Biocept financial statements analysis is a perfect complement when working with Biocept Valuation or Volatility modules.
Biocept | Net Income From Continuing Ops | Build AI portfolio with Biocept Stock |
Evaluating Biocept's Net Income From Continuing Ops across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Biocept's fundamental strength.
Latest Biocept's Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Biocept over the last few years. It is Biocept's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Biocept's overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Biocept Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (25,145,465) | |
| Coefficient Of Variation | (27.00) | |
| Mean Deviation | 3,498,140 | |
| Median | (25,138,039) | |
| Standard Deviation | 6,788,727 | |
| Sample Variance | 46.1T | |
| Range | 29.3M | |
| R-Value | (0.16) | |
| Mean Square Error | 47.8T | |
| R-Squared | 0.03 | |
| Significance | 0.53 | |
| Slope | (221,288) | |
| Total Sum of Squares | 737.4T |
Biocept Net Income From Continuing Ops History
About Biocept Financial Statements
Biocept shareholders use historical fundamental indicators, such as Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although Biocept investors may analyze each financial statement separately, they are all interrelated. The changes in Biocept's assets and liabilities, for example, are also reflected in the revenues and expenses on on Biocept's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Loss | -28.9 M | -30.3 M |
Additional Tools for Biocept Stock Analysis
When running Biocept's price analysis, check to measure Biocept's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biocept is operating at the current time. Most of Biocept's value examination focuses on studying past and present price action to predict the probability of Biocept's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biocept's price. Additionally, you may evaluate how the addition of Biocept to your portfolios can decrease your overall portfolio volatility.